HOME >> MEDICINE >> NEWS
Exploring better ways to determine when to change the course of treatment

Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help doctors determine when or if a change in treatment should be made. The results of a large, multicenter, international study laying the groundwork for such decisions were presented today at the Annual Meeting of the American Society of Clinical Oncology. The study showed the number of circulating tumor cells, or CTC, is a significant predictor of survival and cancer progression.

Few studies have examined the relationship of CTC and a patient's prognosis in cancer. This is an important area of research in metastatic colorectal cancer because there are little data to help physicians chose which treatment is best for which patients or to determine when a change in treatment is warranted.

"If we had a way to know early on that a tumor isn't responding to a particular drug, we could switch to a different treatment before growth of the cancer is seen on a CAT scan," said Neal J. Meropol, director of the gastrointestinal cancer program at Fox Chase Cancer Center and lead investigator of the study. "If we could determine that the tumor was destined to grow after a few weeks of treatment, we'd be able alter course even before the first scan."

For this study, Meropol and his colleagues examined the association between the circulating tumor cell number and progression-free and overall survival for 430 adult patients with metastatic colorectal cancer.

The number of CTC was measured at baseline, one month, and several other points after the start of treatment. CTC were isolated and counted by an immunomagnetic cell separation technique, an FDA-approved technology developed by Immunicon Corporation (Nasdaq-Global Market: IMMC}. CT scans were obtained in usual practiceat baseline and every 6-12 weeks after starting treatment.

Having 3 or more CTC (per 7.5 mL of blood) was defined as "unfavo
'"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
215-728-9751
Fox Chase Cancer Center
3-Jun-2007


Page: 1 2

Related medicine news :

1. Exploring the molecular origin of blood clot flexibility
2. Exploring the potential of cholesterol-lowering drugs for patients with systemic sclerosis
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
5. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Holograms make for better vision tests
9. Parents of chronically ill kids are helped by better access to federal and employer leave
10. Diabetes professionals join forces to identify gaps in diabetes care and better self care
11. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 06, 2016 , ... 'Tis the season for family, festivity, food and fun! ... the season when eating healthy, staying active, and taking medication and doing daily foot ... do. , "Shopping trips, parties and family gatherings can take their toll on ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... program focused on providing occupational safety and health training to public sector employees. ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD ... the arrival of the newest Sciton laser in January 2017. The Halo is ... non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins ... growing brains of young athletes. Over the course of three years, researchers will study ... mouth guards. The mouth guards, equipped with special sensors, will track the location and ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... provide alerting technology to Central Illinois Health Information Exchange (CIHIE) using its ... funds as the sole sub-recipient participating with the Illinois Health Information Exchange ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sangamo BioSciences, ... genome editing, announced the presentation of preclinical and manufacturing data ... at the 58 th Annual Meeting of the American ... Diego, CA , from December 3-6, 2016. ... of hemophilia A which we believe is highly competitive, and ...
(Date:12/5/2016)... 2016  Cornerstone Pharmaceuticals, Inc., a privately held, ... two Phase I trials evaluating its lead compound, ... meeting of the American Society of Hematology (ASH) ... The two datasets show encouraging efficacy and safety ... and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, supporting ...
Breaking Medicine Technology:
Cached News: